Table 3.

Management recommendations for BTKis with CYP3A modulators and selected interactors.

Interacting Agents	Ibrutinib	Acalabrutinib	Zanubrutinib
Strong CYP3A inhibitors	avoid	avoid	80 mg OD
Moderate CYP3A inhibitors	280 mg OD 140 mg OD with voriconazole 70 mg OD with posaconazole	100 mg OD	80 mg BID
Strong CYP3A inducers	avoid	avoid	avoid
PPI	-	avoid	-
Grapefruit, St John’s wort, Seville Oranges	avoid	avoid	80 mg BID
Warfarin/ Vit K antagonists	avoid	avoid	avoid

OD: once daily; BID: bis in die; PPI: proton pump inhibitors.